Foghorn Therapeutics(FHTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 Dosing of first patient in a Phase 1 trial for FHD-909, a potential first-in-class SMARCA2 selective inhibitor, anticipated in the second half of 2024; primary target population in SMARCA4 mutated NSCLC IND-enabling studies for Selective CBP degrader ...